These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 23117771)

  • 1. Transforming clinical trials in cardiovascular disease: mission critical for health and economic well-being.
    Antman EM; Harrington RA
    JAMA; 2012 Nov; 308(17):1743-4. PubMed ID: 23117771
    [No Abstract]   [Full Text] [Related]  

  • 2. [American Heart Association conference 2008. The JUPITER trial, the approval of prasugrel, the (aging) heart of obese adolescents].
    Schaerlig E
    Rev Med Suisse; 2009 Feb; 5(192):482-5. PubMed ID: 19317316
    [No Abstract]   [Full Text] [Related]  

  • 3. Inclusion of comparative effectiveness data in high-risk cardiovascular device studies at the time of premarket approval.
    Chen CE; Dhruva SS; Redberg RF
    JAMA; 2012 Nov; 308(17):1740-2. PubMed ID: 23117769
    [No Abstract]   [Full Text] [Related]  

  • 4. COX-2 inhibitors--lessons in drug safety.
    Psaty BM; Furberg CD
    N Engl J Med; 2005 Mar; 352(11):1133-5. PubMed ID: 15713946
    [No Abstract]   [Full Text] [Related]  

  • 5. American Heart Association 2014 Scientific Sessions.
    J Diabetes; 2015 May; 7(3):299-301. PubMed ID: 25581369
    [No Abstract]   [Full Text] [Related]  

  • 6. Building comparative efficacy and tolerability into the FDA approval process.
    O'Connor AB
    JAMA; 2010 Mar; 303(10):979-80. PubMed ID: 20215612
    [No Abstract]   [Full Text] [Related]  

  • 7. Viewing cardiovascular research through the eyes of past, present, and future generations.
    Peterson ED; Gaziano JM
    JAMA; 2012 Nov; 308(17):1809-10. PubMed ID: 23117784
    [No Abstract]   [Full Text] [Related]  

  • 8. Expectations for comparative effectiveness and efficacy research: with welcomed questions may come unwelcome answers.
    Eaglstein WH; Kirsner RS
    JAMA Dermatol; 2013 Jan; 149(1):18-9. PubMed ID: 23324750
    [No Abstract]   [Full Text] [Related]  

  • 9. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Role of government agencies regarding cost-effectiveness claims: FDA perspective.
    Temple R
    Am Heart J; 1999 May; 137(5):S75-7. PubMed ID: 10220602
    [No Abstract]   [Full Text] [Related]  

  • 10. Reforming cardiovascular care: quality measurement and improvement, and pay-for-performance.
    Dennison CR; Hughes S
    J Cardiovasc Nurs; 2009; 24(5):341-3. PubMed ID: 19707095
    [No Abstract]   [Full Text] [Related]  

  • 11. The economic burden of chronic cardiovascular disease for major insurers.
    Trogdon JG; Finkelstein EA; Nwaise IA; Tangka FK; Orenstein D
    Health Promot Pract; 2007 Jul; 8(3):234-42. PubMed ID: 17606951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating Value Series.
    Ho PM
    Circ Cardiovasc Qual Outcomes; 2017 Jan; 10(1):. PubMed ID: 28093400
    [No Abstract]   [Full Text] [Related]  

  • 13. Costs of occupational circulatory disease.
    Leigh JP; Schnall P
    Occup Med; 2000; 15(1):257-67, v. PubMed ID: 10702089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overhauling clinical trials.
    Scott CT; Baker M
    Nat Biotechnol; 2007 Mar; 25(3):287-92. PubMed ID: 17344876
    [No Abstract]   [Full Text] [Related]  

  • 15. Evidence strength in FDA premarket approval of cardiovascular devices.
    Kong DF; Hasselblad V; Krucoff MW
    JAMA; 2010 Apr; 303(16):1599-600; author reply 1600-1. PubMed ID: 20424248
    [No Abstract]   [Full Text] [Related]  

  • 16. Advances in cardiovascular pharmacology: protocol design and methodology--the US regulatory process.
    Somberg JC; Borer JS
    Am J Ther; 1999 May; 6(3):175-8. PubMed ID: 10423661
    [No Abstract]   [Full Text] [Related]  

  • 17. By Jove! What is a clinician to make of JUPITER?
    Kaul S; Morrissey RP; Diamond GA
    Arch Intern Med; 2010 Jun; 170(12):1073-7. PubMed ID: 20585074
    [No Abstract]   [Full Text] [Related]  

  • 18. Financial Hardship From Medical Bills Among Nonelderly U.S. Adults With Atherosclerotic Cardiovascular Disease.
    Valero-Elizondo J; Khera R; Saxena A; Grandhi GR; Virani SS; Butler J; Samad Z; Desai NR; Krumholz HM; Nasir K
    J Am Coll Cardiol; 2019 Feb; 73(6):727-732. PubMed ID: 30765039
    [No Abstract]   [Full Text] [Related]  

  • 19. Cardiovascular Safety Outcome Trials: A meeting report from the Cardiac Safety Research Consortium.
    Sager PT; Seltzer J; Turner JR; Anderson JL; Hiatt WR; Kowey P; Prochaska JJ; Stockbridge N; White WB
    Am Heart J; 2015 Apr; 169(4):486-95. PubMed ID: 25819855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protocol design.
    Wilensky AJ
    Epilepsy Res Suppl; 1993; 10():107-13. PubMed ID: 8251086
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.